Revive Therapeutics Ltd. (RVVTF)
- Previous Close
0.0151 - Open
0.0156 - Bid 0.0140 x --
- Ask 0.0156 x --
- Day's Range
0.0156 - 0.0184 - 52 Week Range
0.0130 - 0.0460 - Volume
66,522 - Avg. Volume
202,336 - Market Cap (intraday)
5.592M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Jun 10, 2024 - Jun 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. The company is based in Toronto, Canada.
revivethera.com--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: RVVTF
Performance Overview: RVVTF
Trailing total returns as of 6/10/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RVVTF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RVVTF
Valuation Measures
Market Cap
5.24M
Enterprise Value
4.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.81
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.77
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.82%
Return on Equity (ttm)
-39.01%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.23M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.05M
Total Debt/Equity (mrq)
0.63%
Levered Free Cash Flow (ttm)
-2.36M
Company Insights: RVVTF
RVVTF does not have Company Insights